Post-Earnings Insight - Johnson and Johnson

LONDON, October 16, 2014 /PRNewswire/ --

Investor-Edge.com has issued free post-earnings insight on Johnson & Johnson (NYSE: JNJ). On October 14, 2014, the company reported its financial results for Q3 FY14. Click on http://www.investor-edge.com/FreeReports to read our free earnings review on Johnson and Johnson. During Q3 FY14, Johnson & Johnson's net sales and net earnings surged 5.1% and 59.3%, respectively on a Y-o-Y basis and diluted EPS increased $0.62 from the preceding year quarter. Our free coverage report can be accessed at:

http://www.investor-edge.com/register

Earnings Overview 

During Q3 FY14, Johnson & Johnson reported net sales of $18,467 million, compared to $17,575 million in the same period last year. The company's net sales during the reported quarter came marginally above the Bloomberg analysts' forecast of $18,391 million. In Q3 FY14, the company's domestic sales increased 11.6%, while international sales decreased 0.3%, reflecting operational growth of 1.0% and a negative currency impact of 1.3%. During Q3 FY14, the company completed the divestiture of the Ortho-Clinical Diagnostics business. Excluding the impact of this divestiture, worldwide, domestic and international operational sales growth were 8.4%, 14.8% and 3.1% respectively. The free research on JNJ can be downloaded as in PDF format at:

http://www.Investor-Edge.com/JNJFreeReport

Johnson & Johnson's worldwide pharmaceutical sales in Q3 FY14 increased 18.1% Y-o-Y to $8,307 million, with operational growth of 18.7% and a negative impact from currency of 0.6%. The increased worldwide pharmaceutical sales during Q3 FY14 were driven by new products and the strength of the company's core products. On the other hand, worldwide consumer sales decreased 0.6% Y-o-Y to $3,589 million in Q3 FY14, with operational growth of 0.3% and a negative impact from currency of 0.9%. The divestiture of the North American sanitary protection business affected operational growth of consumer sales by approximately 2% worldwide and 5% in the U.S. Additionally, worldwide medical devices and diagnostics sales fell 5.2% Y-o-Y to $6,571 million, consisting of an operational decrease of 4.6% and a negative currency impact of 0.6% during the reported quarter.

Johnson & Johnson's net income broadened to $4,749 million, or $1.66 per diluted share in Q3 FY14, from $2,982 million, or $1.04 per diluted share in the same quarter last year. Analysts from Bloomberg had expected the company to report net income of $4,140 million, or $1.44 per diluted share in Q3 FY14. Excluding some special items, net earnings for Q3 FY14 was $4,292 million, up 9.5% Y-o-Y or $1.50 per diluted share, up 10.3% Y-o-Y. Sign up and read the free analyst's notes on JNJ at:

http://www.Investor-Edge.com/JNJ-16102014

Alex Gorsky, Chairman and Chief Executive Officer of Johnson & Johnson, commented that the company's strong Q3 FY14 performance reflects the continued success of its new products and the strength of its core business. The company is making deliberate portfolio choices, positioning it well for achieving its near-term priorities and its long-term growth drivers. Mr. Gorsky further said that he is proud of all of his colleagues around the world who are focused everyday on delivering solutions to address the evolving health care needs.

The company announced a share repurchase program of up to $5.0 billion of its common stock in the month of July 2014. However, repurchase program has no time limit and it may suspended for periods or discontinued at any time, at management's discretion. Visit Investor-Edge and access the latest research on JNJ at:

http://www.Investor-Edge.com/JNJEarningsCoverage

In its guidance for fiscal 2014, the company increased its earnings guidance between $5.92 and $5.97 per share, excluding the impact of special items.

Stock Performance 

On the day of the earnings release, October 14, 2014, Johnson & Johnson's stock ended the session at $97.01, losing 2.13% for the day. While, on the last close, Wednesday, October 15, 2014; it finished at $98.21, which is 1.24% above its previous day's closing price, after vacillating between $95.10 and $98.72 during the session. A total of 21.89 million shares were traded, which was much above its three months average volume of 6.93 million shares. Over the previous three trading sessions and last one month, the company's shares have fallen by 2.98% and 6.22%, respectively. However, the stock has gained 7.23% from the beginning of 2014. Shares in Johnson & Johnson are trading below their 50-day and 200-day moving averages of $103.73 and $99.35, respectively. Furthermore, the stock traded at a PE ratio of 16.36 and has a Relative Strength Index (RSI) of 28.47.

Sneak Peek to Corporate Insider Trading 

In the last one month Johnson & Johnson has not reported any share transactions by insiders to the U.S. Securities and Exchange Commission (SEC). Complimentary in-depth research on JNJ is available at:

http://www.Investor-Edge.com/JNJInsiderTrading

About Investor-Edge.com 

At Investor-Edge, we provide our members with a simple and reliable way to leverage our economy of scale. Most investors do not have time to track all publicly traded companies, much less perform an in-depth review and analysis of the complexities contained in each situation. That's where Investor-Edge comes in. We provide a single unified platform for investors' to hear about what matters. Situation alerts, moving events, and upcoming opportunities.

===============

EDITOR'S NOTES:

===============

1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.

2. Information in this release is produced on a best efforts basis by Rohit Tuli, a CFA charterholder. The content is then further fact checked and reviewed by an outsourced research provider. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.

3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.

4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco [at] http://www.investor-edge.com.

5. For any urgent concerns or inquiries, please contact us at compliance [at] http://www.investor-edge.com.

6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research [at] http://www.investor-edge.com for consideration.

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Investor-Edge, represented by Rohit Tuli, CFA. An outsourced research services provider has only reviewed the information provided by Investor-Edge in this article or report according to the procedures outlined by Investor-Edge. Investor-Edge is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

NOT FINANCIAL ADVICE

Investor-Edge makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Investor-Edge is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Investor-Edge whatsoever for any direct, indirect or consequential loss arising from the use of this document. Investor-Edge expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Investor-Edge does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE Investor-Edge

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+
Newsrooms &
Influencers

9k+
Digital Media
Outlets

270k+
Journalists
Opted In

GET STARTED